Effect of deferoxamine and L-arginine treatment on lipid peroxidation in an intestinal ischaemia-reperfusion model in rats.
This study investigated lipid peroxidation (LPO) changes during intestinal ischaemia-reperfusion with and without deferoxamine or L-arginine treatment. White Wistar rats were allotted into four groups as follows: sham-operated (Group SOP), ischaemia-reperfusion only (Group I/R), I/R with deferoxamine (Group D) or L-arginine (Group A) treatment. Concentration of thiobarbituric acid reactive substances (TBARS), overall concentration of malondialdehyde and 4-hydroxy-alkenals (LPO586), activities of superoxide dismutase (SOD) and glutathione peroxidase (GPX) of the jejunal homogenates were determined. The same analytes except LPO586 were assayed in RBC haemolysates. Measurements of ferric reducing ability (FRAP), total antioxidant status (TAS) and nitric oxide (NO) concentrations of plasma samples were also completed. The only significant change observed in the SOP group was an increased SOD activity after the ischaemic period. In the I/R group significant increase of intestinal LPO586 concentration was observed during hypoxia that was followed by similar changes in intestinal and RBC TBARS and plasma FRAP values upon reperfusion. In Group D the intestinal TBARS and LPO586 concentrations were significantly lower while FRAP and NO concentrations were significantly higher compared to the I/R group. At the same time RBC TBARS concentration and GPX activity significantly decreased within Group D. In Group A the intestinal LPO586 concentration was significantly lower than in the I/R group whilst RBC TBARS concentration showed a similar pattern. Plasma FRAP and NO concentration showed similar changes to those seen in Group D. It is concluded that I/R increased the LPO in the intestinal tissue and altered some parameters of plasma and RBCs, too. Deferoxamine treatment prevented these effects, while the usefulness of L-arginine remained doubtful.
Balogh
N
N
Large Animal Clinic, Faculty of Veterinary Science, Szent István University, H-2225 Ullö, Dóramajor, Hungary. nbalogh@univet.hu
Krausz
F
F
Lévai
P
P
Ribiczeyné
Piroska Sz
PS
Vajdovich
P
P
Gaál
T
T
D000818:Animals; D001120:Arginine / Q000494:pharmacology*; D003676:Deferoxamine / Q000494:pharmacology*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005979:Glutathione Peroxidase / Q000378:metabolism; D007511:Ischemia / Q000378:metabolism*; D007583:Jejunum / Q000378:metabolism; D015227:Lipid Peroxidation; D008315:Malondialdehyde / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D015424:Reperfusion; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D004791:Enzyme Inhibitors; D017392:Thiobarbituric Acid Reactive Substances; D009569:Nitric Oxide; D008315:Malondialdehyde; D001120:Arginine; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D003676:Deferoxamine